| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 4344839 | Neuroscience Letters | 2011 | 6 Pages |
Abstract
⺠Neurocognitive impairment is a central clinical feature of schizophrenia. ⺠Cognitive impairment in schizophrenia is an important target for treatments. ⺠Typical and atypical antipsychotics may improve cognitive impairment in schizophrenia. ⺠Cognitive improvement with typical and atypical antipsychotics may be small. ⺠Atypical antipsychotics may be superior to typical ones in some cognitive domains.
Related Topics
Life Sciences
Neuroscience
Neuroscience (General)
Authors
Xiaofeng Guo, Jinguo Zhai, Qinling Wei, Elizabeth W. Twamley, Hua Jin, Maosheng Fang, Maorong Hu, Jingping Zhao, For the Early-stage Schizophrenia Outcome Study (ESOS) investigators For the Early-stage Schizophrenia Outcome Study (ESOS) investigators,